Hot Topics in PVD: New Drugs, New Trials Across the Spectrum of Pulmonary Hypertension in Heart and Lung Disease
20 February, 2024 3:00 p.m. to 4:00 p.m. EST
This webinar will highlight new results from therapeutic studies of PAH, specifically Phase Two and Three Studies in Group 1 PAH, and will present information on new concepts for future PAH trials. Participants will learn the practical concerns for PAH
RCT’s including sample size and study design as well as the relevance of primary and secondary endpoints to clinical practice and discuss any ethical issues.
Moderators
Helen Whitford, MBBS, FRACP
Marc Simon, MD, MS,
Presentations
Click any of the drop downs below to learn more about the specific talks being presented as part of this webinar.
Discussion of Phase Two and Three Studies of Sotatercept, Seralutinib, and Anastrazole for Group 1 PAH.
Presented by Clara Hjalmarsson, MD, PhD
Led by Moderators
This presentation will cover disease modification and how clinical trials can be designed to reflect mechanism. Participants will learn the practical concerns for PAH RCT’s including sample size and study design as well as the relevance of primary and secondary endpoints to clinical practice and ethical issues. Topics that will be covered in this area include target patient
Presented by Arun Jose, MD, MS
Led by Moderators
